I will give them until the end of this month....to see if the...

I will give them until the end of this month....to see if the promised DIPG data arrives. Should the data not arrive - then a more proactive imitative will be put into place.

See some background in this thread.....to the individual person - our biggest shareholder, who I would specially approach, to help in general, and commence proceedings to replace the Chairman.

------------------------
My letter to the past CEO - and his reply below. Generally speaking, with the passing of time - I wonder which, his or my correspondence - was to prove the most accurate summation of the situation of how the company was being run then and up until now.

SP was 60 cents at the time and more than 200% shares have been issued.

When it was said no raisings for a certain period of time - and that proved not to be the case in this instance in 2020 - and that was the key point of my letter, though.

What has held things back - is that some shareholders still think the company is doing an OK job on our behalf.

The fund-raising approach is indeed lazy - a more targeted approach to US backers of this small biotech sector......... could have seen cash placed to groups interested in the longer-term development of the company. Easy and simple to source these potential backers of Kazia, via google.

But true laziness has prevailed here......with their fund raisings and an inability to promote the potential of this drug.

Next time the Chairman drafts the wording "without the need for warrants" in summary of their frequent raising, I will release copies of his correspondence to me...and then you will see, what I know. (That follows a  80% decline in the SP since he took over)

------------------------------------------------------------------------


G-----Original Message-----
From:
Sent: Friday, 2 October 2020 9:02 AM
To: James Garner <[email protected]>
Cc: Kate Hill <[email protected]>
Subject: MISLEADING DISCLOSURE

.

You will recall my name, from April correspondence. I own over ...... shares at present.

I draft this email to you, with absolute disgust in the misleading disclosure, that you provided in regard to this weeks major capital raise.

I recently purchased more shares, following your specific and unequivocal advice in a recent company updates, that no raisings would take place, prior to forthcoming data releases.

It particularity irritates me, that in the Kazia presentation yesterday, this comment " we have cash at bank to last us well into CY2021 "  If that is so, why then this major raise now ?

More to the point thought, is the fact of this  misleading disclosure breach.

I am currently drafting a letter to ASIC , to seek their investigation in the actions by Kazia. A quick google search shows severe penalties for what may be, much less. As a shareholder, it is my prerogative to contact ASIC, in such matters.

I believe this decision to raise this week is the initiative of the ultra conservative Chairman.  However you are the person James, who made the declaration, of no capital raises until after the data releases.

You need to stand up for yourself James. To be honest, I don't know how you can look yourself in the mirror, following your advice to shareholders. For this to happen, I think it is dishonest and certainly a major breach of trust to loyal shareholders. Nobody could argue with that.

Anyway shortly the matter will be with the ASIC. You may ask why am I doing this, as a shareholder. My efforts in this regard are for the company long-term and specifically, are directed at seeing the
Chairman depart the company.   ----

=================================================================
Thank you for your note.

I have certainly never said that we would not raise capital prior to any particular date. Our Appendix 4C filing states that the company's runway is to Q2 CY2021, and this is accurately referenced in some of the materials around our current transaction. However, no responsible CEO or Board would wait until the last minute to finance the company, especially in a market as volatile as this.

As we have made clear, the proceeds of this transaction will be used to fund the GBM AGILE pivotal study. Clearly, it would be very unwise to commence the study without being highly confident of being able to see it through, and that is what the transaction we have announced today is designed to ensure. Moreover, it provides an opportunity for existing shareholders to top up their position at a modest discount before the company heads into what is anticipated to be a period of frequent newsflow, and I know that many of our shareholders are very pleased to be able to do so. I and the other Directors will be participating.

I do recall your grievances at our last financing round. However, using the proceeds of that financing, we have been able to more than double the share price of the company, nearly triple its market capitalisation, launch a new clinical trial, and position our lead program on a direct path to commercialisation. I would respectfully put it to you that our success in the intervening period has vindicated our approach, and I can assure you that all of us will be working hard in coming month to ensure that success continues.

All best wishes,